Fda approves netarsudil rhopressa december 18 2017?

Did the FDA approve Rhopressa (netarsudil) on December 18, 2017?

Yes. The FDA approval date for Rhopressa (netarsudil ophthalmic solution) is December 18, 2017.

What was Rhopressa approved to treat?

Rhopressa (netarsudil) was approved for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Why was Rhopressa approved then (and what does that mean for availability)?

An FDA approval on December 18, 2017 means the drug could begin being marketed in the US after that date, subject to normal post-approval launch activities by the manufacturer. If you need exact first-marketing timing, that is often driven by distribution and label availability rather than the approval day itself.

Where can I verify the approval date and related drug details?

You can cross-check the approval and other regulatory details via DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Rhopressa” or “netarsudil”).

Sources

1. DrugPatentWatch.com